Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment

Summary

Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection. This study aims to better understand the potential of both hybrid and igh-dose dual therapies in the treatment of H. pylori infection. .

Timeline

Start

2018-09-01

Primary completion

2021-11-30

Completion

2022-02-28

Outcome

Missed primary endpoint

paper CONCLUSION: This study demonstrated that 14-day rabeprazole-containing HDDT did not achieve >90% eradication rates for first-line H. pylori eradication as 14-day rabeprazole-containing HT did. PMID 37133673 ↗

Publications

• Tai WC, Yang SC, Yao CC, Wu CK, Liu AC, Lee CH, Kuo YH, Chuah SK, Liang CM. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naive Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial. Infect Dis Ther. 2023 May;12(5):1415-1427. doi: 10.1007/s40121-023-00811-3. Epub 2023 May 3.

Drugs

Indications